Free Trial

Biogen (BIIB) Stock Forecast & Price Target

Biogen logo
$119.51 +1.34 (+1.13%)
As of 04/24/2025 04:00 PM Eastern

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
18
Buy
13

Based on 31 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 31 analysts, 18 have given a hold rating, and 13 have given a buy rating for BIIB.

Consensus Price Target

$211.37
76.86% Upside
According to the 31 analysts' twelve-month price targets for Biogen, the average price target is $211.37. The highest price target for BIIB is $342.00, while the lowest price target for BIIB is $135.00. The average price target represents a forecasted upside of 76.86% from the current price of $119.51.
Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

Sign Up

BIIB Analyst Ratings Over Time

TypeCurrent Forecast
4/25/24 to 4/25/25
1 Month Ago
3/26/24 to 3/26/25
3 Months Ago
1/26/24 to 1/25/25
1 Year Ago
4/26/23 to 4/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
13 Buy rating(s)
12 Buy rating(s)
18 Buy rating(s)
Hold
18 Hold rating(s)
17 Hold rating(s)
16 Hold rating(s)
9 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$211.37$213.33$230.00$293.88
Forecasted Upside76.86% Upside49.78% Upside57.32% Upside45.16% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Biogen Stock vs. The Competition

TypeBiogenMedical CompaniesS&P 500
Consensus Rating Score
2.42
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside76.86% Upside2,776.92% Upside21.30% Upside
News Sentiment Rating
Positive News

See Recent BIIB News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/23/2025The Goldman Sachs Group
3 of 5 stars
Salveen Richter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$219.00 ➝ $197.00+63.72%
4/22/2025Royal Bank of Canada
4 of 5 stars
Brian Abrahams
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$221.00 ➝ $225.00+91.28%
4/16/2025Needham & Company LLC
2 of 5 stars
A. Fadia
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/9/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Matthew Harrison
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$157.00 ➝ $152.00+36.93%
4/4/2025Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jasper Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
2/18/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Christopher Raymond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$138.00 ➝ $135.00-2.59%
2/13/2025Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
George Farmer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetSector Outperform ➝ Sector Outperform$244.00 ➝ $224.00+61.69%
2/13/2025BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Seigerman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Perform ➝ Market Perform$156.00 ➝ $139.00+1.30%
2/13/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Meacham
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$160.00 ➝ $145.00+6.96%
2/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetEqual Weight ➝ Equal Weight$165.00 ➝ $140.00+4.40%
2/13/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Srikripa Devarakonda
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$220.00 ➝ $210.00+57.39%
2/13/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andrew Fein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$300.00 ➝ $241.00+80.62%
2/13/2025Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Sumant Kulkarni
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$298.00 ➝ $265.00+98.61%
2/11/2025Bank Of America (Bofa)
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$178.00 ➝ $163.00+16.94%
2/11/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
R. Gal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$160.00+12.25%
1/13/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
12/16/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$175.00+16.64%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$178.00+13.77%
12/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$250.00 ➝ $180.00+14.08%
11/21/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$251.00 ➝ $207.00+32.69%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoveragePeer Perform
11/15/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$294.00 ➝ $300.00+81.94%
11/4/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$220.00 ➝ $210.00+22.40%
10/31/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetEqual Weight ➝ Equal Weight$190.00 ➝ $180.00+2.18%
10/31/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$270.00 ➝ $255.00+44.75%
10/31/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$300.00 ➝ $275.00+56.24%
10/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Brill
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
10/3/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Verma
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$234.00 ➝ $202.00+9.42%
9/23/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$210.00 ➝ $205.00+4.17%
9/9/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$292.00 ➝ $292.00+46.34%
5/3/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$339.00 ➝ $342.00+57.23%
1/7/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Shrader
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
8/8/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral ➝ Neutral$282.00 ➝ $275.00+1.39%
5/1/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Buy$270.00 ➝ $350.00+15.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:39 AM ET.


Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, April 18, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Biogen Inc.:

  • The current stock price is around $118, which may present a buying opportunity for investors looking for potential growth.
  • Recent institutional investments, including significant stakes from Pacer Advisors and Norges Bank, indicate strong confidence in Biogen Inc.'s future performance.
  • Biogen Inc. has a solid market capitalization of approximately $17.36 billion, suggesting a stable financial foundation for growth and innovation.
  • The company has shown resilience with a price-to-earnings ratio of 10.60, which is relatively low compared to industry averages, potentially indicating undervaluation.
  • Recent insider transactions, while showing some selling, also reflect ongoing confidence from management, as they still hold a significant portion of shares.

Biogen
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Biogen Inc. for these reasons:

  • Despite recent investments, the stock has experienced volatility, with a one-year high of $238 and a low of $110, indicating potential instability.
  • Insider ownership is relatively low at 0.16%, which may suggest a lack of alignment between management and shareholder interests.
  • Recent sales by institutional investors, including Legal & General Group Plc, could signal concerns about the company's short-term prospects.
  • The biotechnology sector is highly competitive and subject to regulatory scrutiny, which can impact Biogen Inc.'s market position and profitability.
  • With a beta of 0.06, the stock is less volatile than the market, which may limit potential high returns for aggressive investors.

BIIB Forecast - Frequently Asked Questions

According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $211.37, with a high forecast of $342.00 and a low forecast of $135.00.

31 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 18 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.

According to analysts, Biogen's stock has a predicted upside of 76.86% based on their 12-month stock forecasts.

Over the previous 90 days, Biogen's stock had 1 downgrade by analysts.

Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.


This page (NASDAQ:BIIB) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners